About Exeltis
Exeltis is a company based in Madrid (Spain) founded in 2003.. Exeltis has completed 1 acquisition, including Quinnova Pharmaceuticals. Exeltis offers products and services including Innovative Treatments and Nutritive Specialties. Exeltis operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
- Headquarter Madrid, Spain
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Exeltis Pharmaceuticals Holding, S.L.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Exeltis
Exeltis offers a comprehensive portfolio of products and services, including Innovative Treatments and Nutritive Specialties. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops solutions for unmet medical needs
Provides nutritional products for health support
Unlock access to complete
Funding Insights of Exeltis
- Total Funding Total Funding
-
Total Rounds
-
- Last Round Last Round
- First Round First Round
- Investors Count Investors Count
Investments & Acquisitions by Exeltis
Exeltis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quinnova Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
-
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Exeltis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Exeltis Comparisons
Competitors of Exeltis
Exeltis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| domain | founded_year | HQ Location |
Respiratory disease drugs for asthma and COPD are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Exeltis
Frequently Asked Questions about Exeltis
When was Exeltis founded?
Exeltis was founded in 2003.
Where is Exeltis located?
Exeltis is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
What does Exeltis do?
Exeltis was founded in 2003 and is headquartered in Madrid, Spain. Therapeutics based on small molecules are developed by the company for conditions in areas such as respiratory health, endocrinology, dermatology, and womens health. The pipeline features products including Trifamox, indicated for upper and lower respiratory tract infections, and Eluzer, used in treating inoperable malignant pleural mesothelioma. Operations focus on pharmaceutical development within these sectors.
Who are the top competitors of Exeltis?
Exeltis's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
What products or services does Exeltis offer?
Exeltis offers Innovative Treatments and Nutritive Specialties.
How many acquisitions has Exeltis made?
Exeltis has made 1 acquisition, including Quinnova Pharmaceuticals.